 To evaluate the potential of DG in primary atherosclerosis prevention in high risk hypertension. Patients with high risk hypertension associated with left ventricular hypertrophy, diabetes mellitus and renal insufficiency were randomized to receive DG herbal capsules 2gmday, or 1gmday or identical placebo capsules in double-blind and parallel fashion for 12 months on top of their anti-hypertensive treatments. Flow-mediated dilation endothelium-dependent dilation, FMD and nitroglycerin-induced dilation endothelium-independent dilation, NTG of brachial artery, and carotid intima-media thickness surrogate atherosclerosis marker, IMT were measured by high resolution B-mode ultrasound. 